deltatrials
Completed PHASE2 INTERVENTIONAL 8-arm NCT02380573

Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease (MB2)

Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease

Sponsor: Texas Alzheimer's Research and Care Consortium

Conditions AD Aging Alzheimer's Disease MCI Mild Cognitive Impairment
Interventions FD&C Blue # 2 Methylene Blue Phenazopyridine hydrochloride
Updated 15 times since 2017 Last updated: Sep 16, 2024 Started: Jul 31, 2015 Primary completion: Apr 21, 2022 Completion: Jul 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on AD and Aging, this trial is completed. The trial is conducted by Texas Alzheimer's Research and Care Consortium and has accumulated 15 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jan 2018 · 11 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Jun 2020 · 12 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~May 2022 · 11 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Mar 2025 · 5 months · monthly snapshot~Mar 2025 – present · 16 months · monthly snapshot

Change History

15 versions recorded

  1. Mar 2025 — Present [monthly]

    Completed PHASE2

  2. Oct 2024 — Mar 2025 [monthly]

    Completed PHASE2

    Status: Unknown → Completed

  3. Sep 2024 — Oct 2024 [monthly]

    Unknown PHASE2

    Status: Active Not Recruiting → Unknown

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Suspended → Active Not Recruiting

▶ Show 10 earlier versions

  1. May 2022 — Sep 2022 [monthly]

    Suspended PHASE2

  2. Jun 2021 — May 2022 [monthly]

    Suspended PHASE2

  3. Jan 2021 — Jun 2021 [monthly]

    Suspended PHASE2

  4. Sep 2020 — Jan 2021 [monthly]

    Suspended PHASE2

  5. Jun 2020 — Sep 2020 [monthly]

    Suspended PHASE2

  6. Jun 2019 — Jun 2020 [monthly]

    Suspended PHASE2

    Status: Active Not Recruiting → Suspended

  7. Jun 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Feb 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Texas Alzheimer's Research and Care Consortium
  • The University of Texas Health Science Center at San Antonio
Data source: The University of Texas Health Science Center at San Antonio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations